Therapeutic nanoparticle delivery vehicles for penetrating mucosal barriers and targeting cells

Background

The targeted delivery of therapeutic agents to mucosal tissues—such as the respiratory, gastrointestinal, and reproductive tracts—represents a critical frontier in pharmacology. These surfaces are primary entry points for pathogens and focal sites for numerous diseases. Consequently, there is a profound clinical need to efficiently transport diverse pharmaceutical payloads, including small molecules, biologics, and nucleic acids, directly to these tissues. Effective mucosal delivery systems are essential for advancing localized disease treatments and developing potent mucosal vaccines while minimizing systemic side effects.

However, current delivery approaches are severely hindered by the complex, viscoelastic, and impermeable nature of mucus barriers. Traditional nanoparticle systems face a fundamental dichotomy that limits their clinical viability. Particles engineered with high surface charges to strongly bind to epithelial cells inevitably become trapped within the dense mucin gel. These charged particles rapidly acquire a mucin protein corona, which halts their diffusion. Conversely, particles designed with completely neutral surfaces successfully diffuse through the mucus layer but subsequently exhibit remarkably poor cellular uptake upon reaching the underlying tissue. This inherent trade-off prevents existing platforms from simultaneously achieving efficient muco-penetration and robust cellular targeting.

Technology

This therapeutic nanoparticle delivery vehicle encapsulates pharmaceutical payloads within a 40 to 400 nm carrier. Its core feature is a dense polymer brush corona formed from a strategic blend of amphiphilic block copolymers, combining neutral polymers with specific ratios of anionic or cationic polymers. By precisely adjusting these stabilizing components, the system allows continuous tuning of the particle’s surface zeta potential between -40 mV and +40 mV. Additionally, the nanoparticles are manufactured using Flash NanoPrecipitation, ensuring scalable production of monodisperse particles with highly controlled surface chemistry.

The platform is uniquely differentiated by overcoming the historical compromise between mucosal penetration and cellular uptake. Traditional nanoparticles either bind strongly to cells but get trapped in viscoelastic mucus, or diffuse easily through mucus but exhibit poor cellular absorption. By utilizing a precisely calibrated surface chemistry, this technology achieves a near-neutral surface that limits mucin protein adsorption, enabling rapid diffusion through mucosal barriers. Simultaneously, the strategic inclusion of charged polymers preserves the vehicle’s ability to be internalized by underlying epithelial and immune cells. This dual-action capability ensures highly efficient, targeted drug delivery, potentially reducing required dosages and minimizing side effects.

Benefits

• Enables efficient penetration and rapid diffusion through complex, viscoelastic mucosal barriers by limiting mucin protein adsorption.
• Improves targeted binding and cellular uptake by underlying epithelial and immune cells, overcoming the limitations of traditional neutral nanoparticles.
• Allows precise, continuous tuning of the nanoparticle’s surface charge (zeta potential) and size to optimize biological interactions for specific treatments.
• Accommodates a highly versatile range of therapeutic payloads, including small molecules, biologics, and nucleic acids like mRNA and siRNA.
• Supports scalable, reproducible, and consistent manufacturing of monodisperse nanoparticles using Flash NanoPrecipitation.
• Enhances targeted drug delivery to respiratory, gastrointestinal, reproductive, and ocular tissues, potentially reducing required therapeutic dosages and minimizing side effects.

Applications

• Respiratory tract drug delivery
• Gastrointestinal targeted therapeutics
• Mucosal vaccine administration
• Ocular disease drug delivery
• Mucosal nucleic acid delivery

Additional info

These 40–400 nm therapeutic delivery vehicles feature a dense polymer brush corona encapsulating pharmaceutical payloads. By blending neutral amphiphilic block copolymers with 1–40 mol% anionic or cationic polymers, the surface zeta potential is tuned from -40 mV to +40 mV. Manufactured via Flash NanoPrecipitation, this architecture minimizes mucin adsorption for mucosal diffusion while facilitating cellular uptake through calibrated charge, enabling efficient transport across viscoelastic barriers to target underlying tissues.